The preliminary clinical trial was carried out with a novel benzomorphan derivative of a non-narcotic analgesic, ID-1229, 2'-hydroxy-2-[γ (p-fluorobenzoyl)-n-propyl]-5, 9-dimethyl-6, 7-benzomorphan (Sumitomo Chemical Co., Ltd.). Employed in the test were five cancer and fourteen leprosy volunteers. All of these patients have had too severe pain to give sufficient relief with an ordinary analgesic. In most cases, one ampule of 15mg/ml of ID-1229 was intramuscularly injected. The clinical analgesic effect and other changes observed were as follows:
(1) The intramuscular injection of 15 mg of ID-1229 was equivalent to that of 30mg of pentazocine in analgesic potency.
(2) Administration of ID-1229 caused potent analgesic and hypnotic effects.
(3) ID-1229 was considered to act synergistically with pentazocine in analgesic effect, because the combination of both drugs increased the respective analgesic potencies.
(4) In the present trial, no influence was observed on respiration, heart rate and liver function.
(5) The administration produced reduction in blood pressure which was, in general, within the safety range.
抄録全体を表示